Oxyphenisatine

Summary

Oxyphenisatine (CHEMBL245807) is an approved small molecule (ATC A06AB01); indicated across 1 condition including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A06AB01
• Indications: 1 condition
• Chemistry: 317.3 Da · C20H15NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL245807
Name	Oxyphenisatine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31315
ATC	A06AB01
Molecular formula	C20H15NO3
Molecular weight	317.3
InChIKey	SJDACOMXKWHBOW-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(C(=O)N2)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O

IUPAC name: 3,3-bis(4-hydroxyphenyl)-1H-indol-2-one

Also known as: Isaphen, NSC-59814, Oxifenisatina, Oxyphenisatin, Oxyphenisatine, oxyphenisatine, OXYPHENISATINE, SID170466393, SID144212248, CO-ADD:0137131, PCL-243

Patent coverage: 951 distinct patent families (2,150 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,144 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADORA3	5.3	AC50	5014	nM	CHEMBL_ACT_25198975
KCNH2	5	AC50	10060	nM	CHEMBL_ACT_25118263

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).